Literature DB >> 16140755

Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking.

Kerstin Lux1, Nico Goerlitz, Stefanie Schlemminger, Luca Perabo, Daniela Goldnau, Jan Endell, Kristin Leike, David M Kofler, Stefan Finke, Michael Hallek, Hildegard Büning.   

Abstract

To allow the direct visualization of viral trafficking, we genetically incorporated enhanced green fluorescent protein (GFP) into the adeno-associated virus (AAV) capsid by replacement of wild-type VP2 by GFP-VP2 fusion proteins. High-titer virus progeny was obtained and used to elucidate the process of nuclear entry. In the absence of adenovirus 5 (Ad5), nuclear translocation of AAV capsids was a slow and inefficient process: at 2 h and 4 h postinfection (p.i.), GFP-VP2-AAV particles were found in the perinuclear area and in nuclear invaginations but not within the nucleus. In Ad5-coinfected cells, isolated GFP-VP2-AAV particles were already detectable in the nucleus at 2 h p.i., suggesting that Ad5 enhanced the nuclear translocation of AAV capsids. The number of cells displaying viral capsids within the nucleus increased slightly over time, independently of helper virus levels, but the majority of the AAV capsids remained in the perinuclear area under all conditions analyzed. In contrast, independently of helper virus and with 10 times less virions per cell already observed at 2 h p.i., viral genomes were visible within the nucleus. Under these conditions and even with prolonged incubation times (up to 11 h p.i.), no intact viral capsids were detectable within the nucleus. In summary, the results show that GFP-tagged AAV particles can be used to study the cellular trafficking and nuclear entry of AAV. Moreover, our findings argue against an efficient nuclear entry mechanism of intact AAV capsids and favor the occurrence of viral uncoating before or during nuclear entry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140755      PMCID: PMC1212592          DOI: 10.1128/JVI.79.18.11776-11787.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.

Authors:  S Zolotukhin; B J Byrne; E Mason; I Zolotukhin; M Potter; K Chesnut; C Summerford; R J Samulski; N Muzyczka
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

3.  Adeno-associated virus RNAs appear in a temporal order and their splicing is stimulated during coinfection with adenovirus.

Authors:  M B Mouw; D J Pintel
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Microtubule-independent motility and nuclear targeting of adenoviruses with fluorescently labeled genomes.

Authors:  J B Glotzer; A I Michou; A Baker; M Saltik; M Cotten
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity.

Authors:  Svenja Bleker; Florian Sonntag; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors.

Authors:  U T Hacker; F M Gerner; H Büning; M Hutter; H Reichenspurner; M Stangl; M Hallek
Journal:  Gene Ther       Date:  2001-06       Impact factor: 5.250

8.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Authors:  A Girod; M Ried; C Wobus; H Lahm; K Leike; J Kleinschmidt; G Deléage; M Hallek
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

9.  Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements.

Authors:  Kerstin Laib Sampaio; Yolaine Cavignac; York-Dieter Stierhof; Christian Sinzger
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein.

Authors:  H Mizukami; N S Young; K E Brown
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

View more
  59 in total

1.  Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome.

Authors:  Bernhard Mani; Claudia Baltzer; Noelia Valle; José M Almendral; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction.

Authors:  Sachiko Hirosue; Karin Senn; Nathalie Clément; Mathieu Nonnenmacher; Laure Gigout; R Michael Linden; Thomas Weber
Journal:  Virology       Date:  2007-06-22       Impact factor: 3.616

3.  Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates.

Authors:  Knut Stieger; Josef Schroeder; Nathalie Provost; Alexandra Mendes-Madeira; Brahim Belbellaa; Guylène Le Meur; Michel Weber; Jack-Yves Deschamps; Birgit Lorenz; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

Review 4.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

5.  Analysis of the viral elements required in the nuclear import of HIV-1 DNA.

Authors:  Lise Rivière; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

6.  Unique characteristics of AAV1, 2, and 5 viral entry, intracellular trafficking, and nuclear import define transduction efficiency in HeLa cells.

Authors:  Nicholas W Keiser; Ziying Yan; Yulong Zhang; Diana C M Lei-Butters; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2011-06-28       Impact factor: 5.695

7.  Cell Cycle-Dependent Expression of Adeno-Associated Virus 2 (AAV2) Rep in Coinfections with Herpes Simplex Virus 1 (HSV-1) Gives Rise to a Mosaic of Cells Replicating either AAV2 or HSV-1.

Authors:  Francesca D Franzoso; Michael Seyffert; Rebecca Vogel; Artur Yakimovich; Bruna de Andrade Pereira; Anita F Meier; Sereina O Sutter; Kurt Tobler; Bernd Vogt; Urs F Greber; Hildegard Büning; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

8.  Incorporation of antigens into viral capsids augments immunogenicity of adeno-associated virus vector-based vaccines.

Authors:  Jan Rybniker; Angela Nowag; Hanna Janicki; Kai Demant; Pia Hartmann; Hildegard Büning
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals.

Authors:  A Asokan; J S Johnson; C Li; R J Samulski
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

10.  BAAV transcytosis requires an interaction with beta-1-4 linked- glucosamine and gp96.

Authors:  Giovanni Di Pasquale; Nikola Kaludov; Mavis Agbandje-McKenna; John A Chiorini
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.